908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue OutlookAugust 11, 2026
Epicrispr, Infinimmune snag combined $165M in VC cashBy AdminBitAugust 11, 20260 Epicrispr Biotechnologies and Infinimmune have closed separate fundraising rounds to advance their respective pipelines for neuromuscular and inflammatory conditions.
